- Home
- DCTH vs STOK Comparison
DCTH vs STOK Comparison
Compare DCTH & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- STOK
- Stock Information
- Founded
- DCTH 1988
- STOK 2014
- Country
- DCTH United States
- STOK United States
- Employees
- DCTH N/A
- STOK N/A
- Industry
- DCTH Medical/Dental Instruments
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- STOK Health Care
- Exchange
- DCTH Nasdaq
- STOK Nasdaq
- Market Cap
- DCTH 518.0M
- STOK 556.7M
- IPO Year
- DCTH N/A
- STOK 2019
- Fundamental
- Price
- DCTH $14.88
- STOK $8.33
- Analyst Decision
- DCTH Strong Buy
- STOK Strong Buy
- Analyst Count
- DCTH 4
- STOK 8
- Target Price
- DCTH $22.25
- STOK $23.83
- AVG Volume (30 Days)
- DCTH 356.0K
- STOK 830.1K
- Earning Date
- DCTH 03-06-2025
- STOK 03-24-2025
- Dividend Yield
- DCTH N/A
- STOK N/A
- EPS Growth
- DCTH N/A
- STOK N/A
- EPS
- DCTH N/A
- STOK N/A
- Revenue
- DCTH $22,644,000.00
- STOK $16,742,999.00
- Revenue This Year
- DCTH $1,672.40
- STOK $105.42
- Revenue Next Year
- DCTH $116.33
- STOK $15.13
- P/E Ratio
- DCTH N/A
- STOK N/A
- Revenue Growth
- DCTH 945.91
- STOK 81.08
- 52 Week Low
- DCTH $3.70
- STOK $5.28
- 52 Week High
- DCTH $16.97
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- DCTH 46.47
- STOK 32.00
- Support Level
- DCTH $15.50
- STOK $9.76
- Resistance Level
- DCTH $16.43
- STOK $11.11
- Average True Range (ATR)
- DCTH 0.72
- STOK 0.88
- MACD
- DCTH -0.25
- STOK -0.30
- Stochastic Oscillator
- DCTH 2.79
- STOK 2.31
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.